- Home
- PRPO vs KZIA Comparison
PRPO vs KZIA Comparison
Compare PRPO & KZIA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PRPO
- KZIA
- Stock Information
- Founded
- PRPO N/A
- KZIA 1994
- Country
- PRPO United States
- KZIA Australia
- Employees
- PRPO N/A
- KZIA N/A
- Industry
- PRPO Biotechnology: Laboratory Analytical Instruments
- KZIA Biotechnology: Pharmaceutical Preparations
- Sector
- PRPO Industrials
- KZIA Health Care
- Exchange
- PRPO Nasdaq
- KZIA Nasdaq
- Market Cap
- PRPO 9.9M
- KZIA 7.8M
- IPO Year
- PRPO N/A
- KZIA 1999
- Fundamental
- Price
- PRPO $6.89
- KZIA $1.08
- Analyst Decision
- PRPO
- KZIA Strong Buy
- Analyst Count
- PRPO 0
- KZIA 2
- Target Price
- PRPO N/A
- KZIA $11.50
- AVG Volume (30 Days)
- PRPO 6.8K
- KZIA 5.5M
- Earning Date
- PRPO 03-28-2025
- KZIA 03-26-2025
- Dividend Yield
- PRPO N/A
- KZIA N/A
- EPS Growth
- PRPO N/A
- KZIA N/A
- EPS
- PRPO N/A
- KZIA N/A
- Revenue
- PRPO $17,411,000.00
- KZIA $1,655,324.00
- Revenue This Year
- PRPO $75.18
- KZIA $806.89
- Revenue Next Year
- PRPO N/A
- KZIA N/A
- P/E Ratio
- PRPO N/A
- KZIA N/A
- Revenue Growth
- PRPO 31.31
- KZIA 248000.00
- 52 Week Low
- PRPO $4.31
- KZIA $1.15
- 52 Week High
- PRPO $7.20
- KZIA $15.80
- Technical
- Relative Strength Index (RSI)
- PRPO 61.15
- KZIA 32.04
- Support Level
- PRPO $6.65
- KZIA $1.31
- Resistance Level
- PRPO $6.90
- KZIA $1.60
- Average True Range (ATR)
- PRPO 0.23
- KZIA 0.26
- MACD
- PRPO 0.02
- KZIA 0.05
- Stochastic Oscillator
- PRPO 84.72
- KZIA 0.64
About PRPO Precipio Inc.
Precipio Inc is a healthcare solutions company focused on cancer diagnostics. It focuses on addressing the problem of cancer misdiagnoses by developing solutions to mitigate the root causes of this problem in the form of diagnostic products, reagents and services. The company operates Clinical Laboratory Improvement Amendments laboratories in both the New Haven, Connecticut and Omaha, Nebraska locations providing essential blood cancer diagnostics to office-based oncologists in many states nationwide. It provides new technologies to the oncology diagnostic laboratory market in the form of HemeScreen and IV-Cell product offerings. The company generates the majority of its revenue from third-party payers.
About KZIA Kazia Therapeutics Limited
Kazia Therapeutics Ltd is an oncology-focused biotechnology company, developing anti-cancer drugs. The group is developing paxalisib, a potential treatment for glioblastoma; Cantrixil, being developed for the treatment of ovarian cancer; and Others. The company is also developing EVT801 for the treatment of various tumors. Maximum of revenue is earned from South Korea.